Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Integrated BioPharma Inc. (INBP : OTC)

• Company Description    Integrated BioPharma, Inc. is a well-established biopharma company serving the varied needs of the nutraceutical, biotech and pharmaceutical industries. Through a number of wholly owned subsidiaries INB develops, manufactures and distributes, worldwide over 130 products. Number of Employees: 153

• Price / Volume Information    Yesterday's Closing Price: $0.19 Daily Weekly Monthly 20 Day Moving Average: 13,151 shares Shares Outstanding: 30.98 (millions) Market Capitalization: $6.04 (millions) Beta: 0.41 52 Week High: $0.42 52 Week Low: $0.17 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -25.86% -29.48% 12 Week -35.02% -39.93% Year To Date -45.07% -50.79%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 225 LONG AVENUE BUILDING 15 - HILLSIDE,NJ 07205 USA ph: 888-319-6962 fax: 973-926-1735 investors@ibiopharma.com http://www.ibiopharma.com

• General Corporate Information    Officers Christina Kay - Co-Chief Executive Officer and Director Riva Sheppard - Co-Chief Executive Officer and Director Dina L. Masi - Chief Financial Officer Robert Canarick - Director Damon DeSantis - Director Peer Information Integrated BioPharma Inc. (GSAC) Integrated BioPharma Inc. (CASIF) Integrated BioPharma Inc. (ALCD.) Integrated BioPharma Inc. (OMNN) Integrated BioPharma Inc. (CGPI.) Integrated BioPharma Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 45811V105 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/26 Next Expected EPS Date: 09/22/26 Share - Related Items Shares Outstanding: 30.98 Most Recent Split Date: (:1) Beta: 0.41 Market Capitalization: $6.04 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/22/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.32 Price/Cash Flow: 2.91 Price / Sales: 0.13 EPS Growth vs. Year Ago Period: -250.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -27.53% vs. Previous Quarter: -10.40% ROE 03/31/26 - -8.32 12/31/25 - -1.02 09/30/25 - 3.32 ROA 03/31/26 - -6.57 12/31/25 - -0.83 09/30/25 - 2.64 Current Ratio 03/31/26 - 3.25 12/31/25 - 5.03 09/30/25 - 4.12 Quick Ratio 03/31/26 - 1.78 12/31/25 - 2.67 09/30/25 - 1.92 Operating Margin 03/31/26 - -3.43 12/31/25 - -0.40 09/30/25 - 1.26 Net Margin 03/31/26 - -3.43 12/31/25 - -0.40 09/30/25 - 1.26 Pre-Tax Margin 03/31/26 - -2.32 12/31/25 - 1.33 09/30/25 - 3.28 Book Value 03/31/26 - 0.61 12/31/25 - 0.64 09/30/25 - 0.66 Inventory Turnover 03/31/26 - 5.07 12/31/25 - 5.02 09/30/25 - 4.71 Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.01 Debt-to-Capital 03/31/26 - 0.42 12/31/25 - 0.46 09/30/25 - 0.51

Powered by Zacks Investment Research ©